Optic Neuritis - It's Going from Bad to Worse!



Fiona Costello, MD, FRCPC

Professor

Departments of Clinical Neurosciences & Surgery Director, Roy & Joan Allen Chair for Sight Research University of Calgary & Hotchkiss Brain Institute



Disclosures

- I have received honoraria or speaker fees from Alexion, Sanofi, Healico Live, Vindico, and Novartis
- I have no conflicts of interest with the contents of this presentation



Objectives

- To discuss the evolving spectrum of optic neuritis including myelin oligodendrocyte glycoprotein antibody associated disease (MOGAD), neuromyelitis optic spectrum disorders (NMOSD), and multiple sclerosis (MS) related optic neuritis subtypes
- To highlight key warning signs that may herald risk of permanent vision loss in patients with optic neuritis
- To review management strategies to optimize visual recovery and neurological outcomes for patients presenting with optic neuritis



Key Points

- The diagnosis of optic neuritis may be challenging in front line care settings where patients are most likely to present
- Much of our understanding about the clinical presentation of optic neuritis has been derived from the Optic Neuritis Treatment Trial (ONTT) experience, yet lessons from the ONTT are not extendable to all optic neuritis subtypes
- It is important to tailor treatment to optimize recovery for all optic neuritis subtypes. Early diagnosis and differentiation are key management strategies that can preserve vision



References

- Petzold A, Fraser CL, Abegg M, et al. Diagnosis and classification of optic neuritis. Lancet Neurol 2022 Dec;21(12):1120-1134
- Bennett JL, Costello F, Chen JJ, Petzold A, Biousse V, Newman NJ, Galetta SL. Optic neuritis and autoimmune optic neuropathies: advances in diagnosis and treatment. Lancet Neurol 2023 Jan;22(1):89-100
- 3. Costello F. Inflammatory optic neuropathies. Continuum (Minneap Minn) 2014 Aug;20(4 Neuro-ophthalmology):816-37
- 4. Bennett JL. Optic Neuritis. Continuum (Minneap Minn) 2019 Oct;25(5):1236-1264

